These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 22898254)

  • 1. Discovery of the investigational drug TAK-441, a pyrrolo[3,2-c]pyridine derivative, as a highly potent and orally active hedgehog signaling inhibitor: modification of the core skeleton for improved solubility.
    Ohashi T; Oguro Y; Tanaka T; Shiokawa Z; Tanaka Y; Shibata S; Sato Y; Yamakawa H; Hattori H; Yamamoto Y; Kondo S; Miyamoto M; Nishihara M; Ishimura Y; Tojo H; Baba A; Sasaki S
    Bioorg Med Chem; 2012 Sep; 20(18):5507-17. PubMed ID: 22898254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of pyrrolo[3,2-c]quinoline-4-one derivatives as novel hedgehog signaling inhibitors.
    Ohashi T; Oguro Y; Tanaka T; Shiokawa Z; Shibata S; Sato Y; Yamakawa H; Hattori H; Yamamoto Y; Kondo S; Miyamoto M; Tojo H; Baba A; Sasaki S
    Bioorg Med Chem; 2012 Sep; 20(18):5496-506. PubMed ID: 22910224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic and pharmacodynamic modeling of hedgehog inhibitor TAK-441 for the inhibition of Gli1 messenger RNA expression and antitumor efficacy in xenografted tumor model mice.
    Kogame A; Tagawa Y; Shibata S; Tojo H; Miyamoto M; Tohyama K; Kondo T; Prakash S; Shyu WC; Asahi S
    Drug Metab Dispos; 2013 Apr; 41(4):727-34. PubMed ID: 23298863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and evaluation of hedgehog signaling inhibitor with novel core system.
    Ohashi T; Tanaka Y; Shiokawa Z; Banno H; Tanaka T; Shibata S; Satoh Y; Yamakawa H; Yamamoto Y; Hattori H; Kondo S; Miyamoto M; Tojo H; Baba A; Sasaki S
    Bioorg Med Chem; 2015 Aug; 23(15):4777-4791. PubMed ID: 26094943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition mechanism exploration of investigational drug TAK-441 as inhibitor against Vismodegib-resistant Smoothened mutant.
    Ishii T; Shimizu Y; Nakashima K; Kondo S; Ogawa K; Sasaki S; Matsui H
    Eur J Pharmacol; 2014 Jan; 723():305-13. PubMed ID: 24291104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent Hedgehog pathway activation.
    Wong H; Alicke B; West KA; Pacheco P; La H; Januario T; Yauch RL; de Sauvage FJ; Gould SE
    Clin Cancer Res; 2011 Jul; 17(14):4682-92. PubMed ID: 21610148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I dose-escalation trial of the oral investigational Hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors.
    Goldman J; Eckhardt SG; Borad MJ; Curtis KK; Hidalgo M; Calvo E; Ryan DP; Wirth LJ; Parikh A; Partyka J; Faessel H; Gangolli E; Stewart S; Rosen LS; Bowles DW
    Clin Cancer Res; 2015 Mar; 21(5):1002-9. PubMed ID: 25501576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A small-molecule antagonist of the hedgehog signaling pathway.
    Lee J; Wu X; Pasca di Magliano M; Peters EC; Wang Y; Hong J; Hebrok M; Ding S; Cho CY; Schultz PG
    Chembiochem; 2007 Nov; 8(16):1916-9. PubMed ID: 17886323
    [No Abstract]   [Full Text] [Related]  

  • 9. GDC-0449-a potent inhibitor of the hedgehog pathway.
    Robarge KD; Brunton SA; Castanedo GM; Cui Y; Dina MS; Goldsmith R; Gould SE; Guichert O; Gunzner JL; Halladay J; Jia W; Khojasteh C; Koehler MF; Kotkow K; La H; Lalonde RL; Lau K; Lee L; Marshall D; Marsters JC; Murray LJ; Qian C; Rubin LL; Salphati L; Stanley MS; Stibbard JH; Sutherlin DP; Ubhayaker S; Wang S; Wong S; Xie M
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5576-81. PubMed ID: 19716296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and biological evaluation of optimized phthalazine derivatives as hedgehog signaling pathway inhibitors.
    Lu X; Peng Y; Wang C; Yang J; Bao X; Dong Q; Zhao W; Tan W; Dong X
    Eur J Med Chem; 2017 Sep; 138():384-395. PubMed ID: 28688278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective targeting of Hedgehog signaling in a medulloblastoma model with PF-5274857, a potent and selective Smoothened antagonist that penetrates the blood-brain barrier.
    Rohner A; Spilker ME; Lam JL; Pascual B; Bartkowski D; Li QJ; Yang AH; Stevens G; Xu M; Wells PA; Planken S; Nair S; Sun S
    Mol Cancer Ther; 2012 Jan; 11(1):57-65. PubMed ID: 22084163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926).
    Tremblay MR; Lescarbeau A; Grogan MJ; Tan E; Lin G; Austad BC; Yu LC; Behnke ML; Nair SJ; Hagel M; White K; Conley J; Manna JD; Alvarez-Diez TM; Hoyt J; Woodward CN; Sydor JR; Pink M; MacDougall J; Campbell MJ; Cushing J; Ferguson J; Curtis MS; McGovern K; Read MA; Palombella VJ; Adams J; Castro AC
    J Med Chem; 2009 Jul; 52(14):4400-18. PubMed ID: 19522463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TAK-441, a novel investigational smoothened antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling.
    Ibuki N; Ghaffari M; Pandey M; Iu I; Fazli L; Kashiwagi M; Tojo H; Nakanishi O; Gleave ME; Cox ME
    Int J Cancer; 2013 Oct; 133(8):1955-66. PubMed ID: 23564295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of novel 4-(2-pyrimidinylamino)benzamide derivatives as highly potent and orally available hedgehog signaling pathway inhibitors.
    Xin M; Zhang L; Jin Q; Tang F; Wen J; Gu L; Cheng L; Zhao Y
    Eur J Med Chem; 2016 Mar; 110():115-25. PubMed ID: 26820554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, Synthesis, and Structure-Activity Relationship of Tetrahydropyrido[4,3-d]pyrimidine Derivatives as Potent Smoothened Antagonists with in Vivo Activity.
    Lu W; Liu Y; Ma H; Zheng J; Tian S; Sun Z; Luo L; Li J; Zhang H; Yang ZJ; Zhang X
    ACS Chem Neurosci; 2017 Sep; 8(9):1980-1994. PubMed ID: 28618224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and evaluation of novel dimethylpyridazine derivatives as hedgehog signaling pathway inhibitors.
    Wang C; Zhu M; Lu X; Wang H; Zhao W; Zhang X; Dong X
    Bioorg Med Chem; 2018 Jul; 26(12):3308-3320. PubMed ID: 29739714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of Novel Macrocyclic Hedgehog Pathway Inhibitors Acting by Suppressing the Gli-Mediated Transcription.
    Liu G; Huang W; Wang J; Liu X; Yang J; Zhang Y; Geng Y; Tan W; Zhang A
    J Med Chem; 2017 Oct; 60(19):8218-8245. PubMed ID: 28873303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and evaluation of hybrid vitamin D3 side chain analogues as hedgehog pathway inhibitors.
    Banerjee U; DeBerardinis AM; Hadden MK
    Bioorg Med Chem; 2015 Feb; 23(3):548-55. PubMed ID: 25549899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitogen-activated kinase kinase kinase 1 inhibits hedgehog signaling and medulloblastoma growth through GLI1 phosphorylation.
    Antonucci L; Di Magno L; D'Amico D; Manni S; Serrao SM; Di Pastena F; Bordone R; Yurtsever ZN; Caimano M; Petroni M; Giorgi A; Schininà ME; Yates Iii JR; Di Marcotullio L; De Smaele E; Checquolo S; Capalbo C; Agostinelli E; Maroder M; Coni S; Canettieri G
    Int J Oncol; 2019 Feb; 54(2):505-514. PubMed ID: 30483764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and evaluation of pyrrolo[2,1-f][1,2,4]triazine derivatives as novel hedgehog signaling pathway inhibitors.
    Xin M; Zhang L; Tang F; Tu C; Wen J; Zhao X; Liu Z; Cheng L; Shen H
    Bioorg Med Chem; 2014 Feb; 22(4):1429-40. PubMed ID: 24486203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.